Patents Assigned to ZymoGenetics, Inc.
  • METHODS FOR USING TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20110229473
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 22, 2011
    Applicant: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Methods of using IL-31 monoclonal antibodies to reduce inflammation
    Patent number: 8017122
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Cytokine zalpha11 ligand antibodies and methods of use
    Patent number: 8017343
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Antibodies to human zcytor17 ligand
    Patent number: 8013124
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: September 6, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Julia E. Novak
  • Method for treating inflammation
    Patent number: 8003104
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 23, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
  • Cytokine zalpha11 ligand antibodies
    Patent number: 7998468
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • MURINE ZCYTOR17 LIGAND POLYNUCLEOTIDES
    Publication number: 20110196128
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 8, 2010
    Publication date: August 11, 2011
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20110177083
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
    Type: Application
    Filed: January 27, 2011
    Publication date: July 21, 2011
    Applicant: Zymogenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Steven D. Levin, Rolf E. Kuestner, Zeren Gao, Stephen R. Jaspers, Janine Bilsborough
  • Production and purification of IL-29
    Patent number: 7968315
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 28, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • SOLUBLE HETERODIMERIC CYTOKINE RECEPTOR
    Publication number: 20110150872
    Abstract: A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Application
    Filed: January 27, 2010
    Publication date: June 23, 2011
    Applicant: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Julia E. Novak, Donald C. Foster, Wenfeng Xu, Stephen R. Jaspers
  • Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
    Patent number: 7964711
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: June 21, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Methods of treating viral infections using IL-21
    Patent number: 7959908
    Abstract: Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known antimicrobial or antiviral therapeutics.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: June 14, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Andrew J. Nelson, Wayne Kindsvogel
  • Methods of stimulating bone growth using ZVEGF4 polypeptides
    Patent number: 7951380
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 31, 2011
    Assignee: Zymogenetics, Inc.
    Inventors: Debra G. Gilbertson, Charles E. Hart
  • TACI-immunoglobulin fusion proteins
    Patent number: 7951919
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: May 31, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Nucleic acid encoding cytokine receptor ZCYTOR17
    Patent number: 7947474
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zyctor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zyctor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: May 24, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Methods of treating pain using antagonists of IL-31, IL-31RA and/or OSMRB
    Patent number: 7943132
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: May 17, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING
    Publication number: 20110110943
    Abstract: Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
    Type: Application
    Filed: November 22, 2010
    Publication date: May 12, 2011
    Applicant: Zymogenetics, Inc.
    Inventors: Jane A. Gross, Wenfeng Xu, Karen L. Madden, David P. Yee
  • Antagonizing signal transduction in dorsal root ganglion cells in a subject with IL-31 antagonists
    Patent number: 7939068
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 10, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • IL-21 antagonists
    Patent number: 7923539
    Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: April 12, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • Antibodies to cytokine receptor zalpha11
    Patent number: 7923212
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: April 12, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond